[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352307-105":59,"doc-detail-352307-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","nf12-mutations-predict-favorable-benefit-from-immune-checkpoint-inhibitor-based-therapies-over-vegfrmtor-inhibitors-in-clear-cell-renal-cell-carcinoma","NF1/2 mutations predict favorable benefit from immune checkpoint inhibitor-based therapies over VEGFR/mTOR inhibitors in clear cell renal cell carcinoma","","Immune checkpoint inhibitors (ICIs) have transformed treatment of advanced clear cell renal cell carcinoma (ccRCC), yet biomarkers that forecast ICI benefit over conventional VEGFR/mTOR inhibitors remain incompletely defined. This study integrated clinical, mutational, and/or transcriptomic data across multiple cohorts, including JAVELIN Renal 101, IMmotion151, and CheckMate-009/010/025 trials and TCGA-KIRC and ICGC cohorts. Only NF1/2 mutations showed a consistent predictive association with superior ICI benefit versus VEGFR/mTOR strategies, supported by pooled interaction analysis and mechanistic links to FGFR-related expression and drug sensitivity.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/nf12-mutations-predict-favorable-benefit-from-immune-checkpoint-inhibitor-based-therapies-over-vegfrmtor-inhibitors-in-clear-cell-renal-cell-carcinoma/352307/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/nf12-mutations-predict-favorable-benefit-from-immune-checkpoint-inhibitor-based-therapies-over-vegfrmtor-inhibitors-in-clear-cell-renal-cell-carcinoma/352307.png","ImageObject",300,407,{"name":92,"@type":93},"Eliana","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-13","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",17,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Which biomarker mutation type predicts favorable benefit from ICIs over VEGFR/mTOR inhibitors in advanced ccRCC?","Question",{"text":113,"@type":114},"Only NF1/2 mutations showed a consistent relationship with ICI-based benefits over VEGFR/mTOR inhibitors across the analyzed common mutations and the pooled trial datasets.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What evidence supports that NF1/2 mutations predict stronger ICI benefit?",{"text":118,"@type":114},"The study reported a significant pooled interaction effect (P = 0.028) across JAVELIN Renal 101, IMmotion151, and CheckMate-009/010/025, and multivariable models showed lower hazard ratios for ICI regimens in NF1/2-mutant versus NF1/2-wildtype groups.",{"name":120,"@type":111,"acceptedAnswer":121},"How do NF1/2 mutations relate to gene expression and drug sensitivity mechanisms?",{"text":122,"@type":114},"NF1/2 mutations were associated with greater expression of FGFR-related genes rather than VEGFR or PI3K-AKT-mTOR genes, and ccRCC cell lines with NF1/2 mutations showed higher sensitivity to FGFR inhibitors than to VEGFR/PI3K-AKT-mTOR inhibitors.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},352307,1790205951,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":41,"preview_page_count":19,"preview_urls":146},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","Clinical and Experimental Medicine (2026) 26:111  \n[https://doi.org/10.1007/s10238-025-01885-8](https://doi.org/10.1007/s10238-025-01885-8)  \nNF1/2 mutations predict favorable benefit from immune checkpoint inhibitor‑based therapies over VEGFR/mTOR inhibitors in clear cell renal cell carcinoma  \nYi Sun2 · Qiang Cheng1 · Qiaoxia Zhou3 · Yu Xu3 · Guoqiang Wang3 · Chunwei Xu4 · Wenxian Wang5 · Shangli Cai3 · Wenzheng Chen1  \nReceived: 22 July 2025 / Accepted: 4 September 2025 © The Author(s) 2026  \nAbstract  \nImmune checkpoint inhibitors (ICIs) have revolutionized the management of advanced clear cell renal cell carcinoma (ccRCC), but the biomarkers predicting benefits from ICI-based therapies over conventional VEGFR/mTOR inhibitors remain incompletely elucidated. In this study, we analyzed clinical, mutational, and/or transcriptomic data of multiple cohorts, including five clinical trials (JAVELIN Renal 101 [n = 885], IMmotion151 [n = 715], and CheckMate-009/010/025 [n = 1006]), two prognostic cohorts (TCGA-KIRC, n = 537; ICGC, n = 475). Pharmacogenomic analysis was conducted using the cancer cell line encyclopedia (CCLE) database. Our results revealed that only NF1/2 mutations exhibited a consistent relationship with benefits from ICI-based therapies over VEGFR/mTOR inhibitors among all the common mutations in the JAVELIN Renal 101, IMmotion151, and CheckMate-009/010/025 trials (pooled estimate of interaction effect, P = 0.028) . In the multivariable models, ICI benefits were higher in the NF1/2-mutant group compared with the NF1/2-wildtype group (avelumab plus axitinib vs. sunitinib: HRmut = 0.35/HRwildtype = 0.64; atezolizumab plus bevacizumab vs. sunitinib: HRmut = 0.55/ HRwildtype = 0.82; nivolumab vs. everolimus: HRmut = 0.17/HRwildtype = 0.73) . NF1/2 mutations were associated with greater expression of the genes related to FGFR rather than VEGFR or PI3K-AKT-mTOR in advanced ccRCCs and higher sensitivity to FGFR inhibitors instead of VEGFR/PI3K-AKT-mTOR inhibitors in ccRCC cell lines. Compared with the NF1/2-wildtype advanced ccRCCs, those with mutated NF1/2 had an inferior prognosis (HR = 2.53). This tendency was not changed by everolimus (HR = 2.66), but was abrogated slightly by sunitinib (HR = 1.59) and considerably by ICI-based therapies, including nivolumab monotherapy (HR = 1.12), atezolizumab plus bevacizumab (HR = 1.10), and avelumab plus axitinib (HR = 0.69) . Overall, our findings suggest that NF1/2 mutations can serve as predictive biomarkers for favorable benefits from ICI-based treatments over VEGFR/mTOR inhibitors in advanced ccRCCs.  \nKeywords Clear cell renal cell carcinomas · NF1/2 mutations · Immunotherapy · Predictive biomarker  \nYi Sun, Qiang Cheng and Qiaoxia Zhou have contributed equally to this work.  \n* Shangli Cai[shangli.cai@brbiotech.com](shangli.cai@brbiotech.com)  \n* Wenzheng Chen [cwz_11@sina.com](cwz_11@sina.com)  \n1 Department of Urology, The Third Medical Centre of Chinese PLA General Hospital, Beijing, China 100853  \n2 Department of Pathology, The Second Xiangya Hospital, Central South University, Changsha 410011, China  \n3 Building 6, Phase 2, Standard Industrial Unit, Burning Rock Biotech, No. 7 LuoXuan 4th Road, International Biotech Island, Guangzhou 510300, China  \n4 Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China  \n5 Department of Clinical Trial, The Cancer Hospital  \nof the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China  \nIntroduction  \nClear cell renal cell carcinoma (ccRCC) is the most prevalent histologic subtype of renal cell carcinomas [1] . Approximately, 20% of patients present with metastatic disease [2] . Over the past decade, substantial advancesin the management of metastatic ccRCC have been achieved with targeted agents, including inhibitors of vascular endothelial growth factor (VEGF) and its receptor (VEGFR) [3], mechanistic target of rapamycin complex 1 (mTORC1) [4], and multi-target ","cbCaieB59jrBP96y","https://ap.wps.com/l/cbCaieB59jrBP96y","pdf",2885232,12,"English","# Abstract\n# Introduction\n## Background of ccRCC treatment and need for biomarkers\n## Prior research on mutation-driven prognostic/predictive signals\n## Rationale for evaluating ICI efficacy by gene mutations","[{\"question\":\"Which biomarker mutation type predicts favorable benefit from ICIs over VEGFR/mTOR inhibitors in advanced ccRCC?\",\"answer\":\"Only NF1/2 mutations showed a consistent relationship with ICI-based benefits over VEGFR/mTOR inhibitors across the analyzed common mutations and the pooled trial datasets.\"},{\"question\":\"What evidence supports that NF1/2 mutations predict stronger ICI benefit?\",\"answer\":\"The study reported a significant pooled interaction effect (P = 0.028) across JAVELIN Renal 101, IMmotion151, and CheckMate-009/010/025, and multivariable models showed lower hazard ratios for ICI regimens in NF1/2-mutant versus NF1/2-wildtype groups.\"},{\"question\":\"How do NF1/2 mutations relate to gene expression and drug sensitivity mechanisms?\",\"answer\":\"NF1/2 mutations were associated with greater expression of FGFR-related genes rather than VEGFR or PI3K-AKT-mTOR genes, and ccRCC cell lines with NF1/2 mutations showed higher sensitivity to FGFR inhibitors than to VEGFR/PI3K-AKT-mTOR inhibitors.\"}]","NF1/2 mutations predict favorable benefit from immune checkpoint inhibitor-based therapies over VEGFR/mTOR inhibitors in clear cell renal cell carcinoma | PDF",1790098846,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b8f31b004076e55525cb9488388406de.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4cafad3a1eace1be1202aabe2fb1305c.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6680d3844a76570bc3f269bb7eb1aa2a.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/850d10704893cddcc1725d14a0a60b40.webp",980,1301]